Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2-Reference-Cited by-同舟云学术

Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2

Published:2023-03-09 Issue:1 Volume:26 Page:357-365
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Cameron David¹^ORCID,Kumar Sharma Vikash²^ORCID,Biswas Chandroday²^ORCID,Clarke Cathy³,Chandiwana David⁴,Pathak Purnima⁴

Affiliation:

1. Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK

2. Novartis Healthcare Pvt Ltd, Hyderabad, India

3. Novartis Pharmaceuticals UK Ltd, London, UK

4. Novartis Services Inc., East Hanover, NJ, USA

Funder

Novartis Pharmaceuticals

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2182051

Reference45 articles.

1. World Health Organization. Breast cancer. 2021. https://www.who.int/news-room/fact-sheets/detail/breast-cancer

2. Cancer Research UK. Breast cancer incidence (invasive) statistics. 2021. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive

3. Extending Survival with Chemotherapy in Metastatic Breast Cancer

4. Metastatic Breast Cancer Network. Incidence and incidence rates. 2022. http://mbcn.org/incidence-and-incidence-rates/

5. Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CANCER THERAPY BY CYCLIN-DEPENDENT KINASE INHIBITORS (CDKIS): BENCH TO BEDSIDE;EXCLI J;2024

2. CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessment;Medicine;2023-10-06

3. Sepsis, a call for inclusion in the work plan of the European Center for Disease Prevention and Control;Intensive Care Medicine;2023-08-01

4. Analysis of the regional clinical use of CDK4/6 inhibitor ribociclib as a mechanism of integration of a research approach in drug provision;Meditsinskiy sovet = Medical Council;2023-07-29